Company: CWAN
Filing Date: 2025-02-11
Form Type: S-4
Source: 0001193125-25-023759
Chunk: 203

Company: Clearwater Analytics Holdings, Inc.
Filing Date: 2025-02-11
Form: S-4
Chunk 203
---
 the accounting methods used by Enfusion materially affecting its assets, liabilities or business,                                                                                             
 except for such changes that are required by GAAP or Regulation S-X promulgated under the Exchange Act or as otherwise specifically disclosed in Enfusion’s reports filed with the SEC prior to the date of 
 the Merger Agreement;                                                                                                                                                                                       |

| • |     | (1) make (other than tax elections made in the ordinary course), change or revoke any material tax election,                                                                                                                            
 (2) change or adopt any tax accounting period or method, (3) file any material amended tax return, (4) fail to pay taxes when due and payable (including estimated tax payments), (5) enter into any closing agreement, (6) settle or   
 compromise any audit or other proceeding with respect to any tax claim or assessment, (7) surrender any right to claim a material tax refund, offset or other reduction in tax liability, (8) request any ruling with respect to taxes, 
 (9) consent to any extension or waiver of the limitation period applicable to any taxes or (10) enter into a voluntary disclosure or similar agreement;                                                                                 |

| • |     | except for borrowings under Enfusion’s credit facility and except for intercompany loans solely between                                                                              
 Enfusion and any of its wholly-owned subsidiaries or between any of its wholly-owned subsidiaries, in each case made in the ordinary course of business, incur, assume, guarantee or |

129

| otherwise become liable for additional indebtedness for borrowed money or issue or sell debt securities or warrants or other rights to acquire any debt securities, or assume, guarantee or endorse 
 any indebtedness for borrowed money of any person (other than a wholly owned subsidiary of Enfusion) in excess of $1,000,000 individually or $3,500,000 in the aggregate;                           |

| • |     | (1) enter into any contract that would have been a Material Contract (as defined in the Merger Agreement) if it                                                                                                                                   
 had been entered into prior to the date of the Merger Agreement, (2) renew or extend any Material Contract, other than renewals or extensions of any expiring contracts without material adverse changes of terms with respect to Enfusion or its 
 subsidiaries (ordinary-course, non-material changes to monetary expenditures under any such contracts will not be deemed to be a material adverse change of terms for this purpose) or (3) modify or amend                                        
 in any material respect or terminate any Material Contract or waive any material right, claim,